Biodexa Pharmaceuticals Plc (BDRX) Form 424B3 — Aug 4, 2026
Biodexa Pharmaceuticals shareholders approved all four resolutions at the July 29, 2026 general meeting, including a one-for-10,000 reverse stock split of the company's ordinary shares that became effective July 30, 2026. Concurrent with the split, the ADS ratio changed from one ADS per 500,000 ordinary shares to one ADS per 50, leaving 51,453,281 ordinary shares outstanding — equivalent to the same 1,029,063 ADSs as before the reorganization. Proportional ownership is unchanged and the company notes the ADS change does not itself constitute a reverse split of the ADSs.
Key figures
- Shares Outstanding
- 51,453,281 ordinary shares outstanding after the reorganization, equivalent to 1,029,063 ADSs (unchanged ADS count)
- Ads outstanding
- 1029063
- Ads ratio after
- one ADS per 50 ordinary shares
- Ads ratio before
- one ADS per 500,000 ordinary shares
- Reverse split ratio
- 1:10,000
- Series l warrant ads
- 1219512
- Last closing price usd
- 1.42
- Pre funded warrant ads
- 97800
- Last closing price date
- 2026-08-03
- Offering completion date
- 2025-12-19
- Placement agent warrant ads
- 30487
- Share allotment authority gbp
- 25000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.